Back to results
US 2023/0147035 A1Published application
Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
AssigneeThe Johns Hopkins University
InventorsSangeeta Ray, Martin G. Pomper
Life of this patent
Estimating the term…
Abstract
Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.
Claims19
A compound of Formula (I):
- wherein:
- Z is tetrazole or CO2Q;
- Q is H or a protecting group;
- m is an integer selected from the group consisting of 1, 2, 3, 4, and 5;
- R is independently H or —CH2—R1;
- R1 is selected from the group consisting of substituted aryl, substituted pyridine, and unsubstituted isoquinoline;
- L is a linker selected from the group consisting of C1-C6 alkylene and C3-C6 cycloalkylene, and arylene;
- W is selected from the group consisting of —NR2—(C═O)—, —NR2—(C═S)—, —(C═O)—NR2—, and —(C═S)—NR2—;
- wherein each occurrence of L and W can be the same or different;
- R2 is H or a C1-C4 alkyl;
- n is an integer selected from the group consisting of 1, 2, and 3;
- Ch is a chelating agent that can comprise a metal or a radiometal;
- and pharmaceutically acceptable salts thereof.
10 more elements
A method for treating one or more PSMA expressing tumors or cells, the method comprising contacting the one or more PSMA expressing tumors or cells with an effective amount of a compound of formula (I), the compound of formula (I) comprising:
- wherein:
- Z is tetrazole or CO2Q;
- Q is H or a protecting group;
- m is an integer selected from the group consisting of 1, 2, 3, 4, and 5;
- R is independently H or —CH2—R1;
- R1 is selected from the group consisting of substituted aryl, substituted pyridine, and unsubstituted isoquinoline;
- L is a linker selected from the group consisting of C1-C6 alkylene and C3-C6 cycloalkylene, and arylene;
- W is selected from the group consisting of —NR2—(C═O)—, —NR2—(C═S)—, —(C═O)—NR2—, and —(C═S)—NR2—;
- wherein each occurrence of L and W can be the same or different;
- R2 is H or a C1-C4 alkyl;
- n is an integer selected from the group consisting of 1, 2, and 3;
- Ch is a chelating agent that comprises a radiometal suitable for radiotherapy;
- and pharmaceutically acceptable salts thereof.
10 more elements
Dependencies are inferred from the claim text.